1 / 22

Chemotherapy-induced nausea and vomiting

Chemotherapy-induced nausea and vomiting. By Alan O’Kane Specialist Pharmacist Oncology and Aseptic Ninewells Hospital. Chemotherapy-induced nausea and vomiting. Most feared side-effect May be more distressing than future concerns of life expectancy

hall
Download Presentation

Chemotherapy-induced nausea and vomiting

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Chemotherapy-induced nauseaand vomiting By Alan O’Kane Specialist Pharmacist Oncology and Aseptic Ninewells Hospital

  2. Chemotherapy-induced nausea and vomiting • Most feared side-effect • May be more distressing than future concerns of life expectancy • Medical complications: dehydration, electrolyte imbalance, risk of aspiration pneumonia • Many treatments palliative intent = maintain QOL • Effective management of N + V is essential

  3. High Risk in nearly all patients (>90%) Moderate Risk in 30-90% of patients Low Risk in 10-30% of patients Minimal Risk in less than 10% of patients. Emetogenic Risk categories for chemotherapy in untreated patients (See Figure 1) Primary Risk Factor

  4. Patient risk factors • Age <50 years • Female • Alcohol intake • Prone to N +V

  5. Substance P GABA Serotonin Nausea Acetylcholine Dopamine Vomiting Histamine ??????? Cannabinoid

  6. Categories of CINV • Acute - within 24 hours of chemotherapy • Delayed - 24 hours to 7 days post chemo • The most effective way of controlling CINV is to prevent symptoms of acute and delayed CINV by using a combination of an NK1 antagonist, 5HT3 antagonist and dexamethasone.

  7. Anatomy of CINV • Brainstem vomiting enter1,2 • Area postrema • Chemoreceptor trigger zone (CTZ) • Nucleus tractus solitarius • Dorsal motor nucleus of the vagus nerve • Substance P/neurokinin 1 (NK1)receptors1 • Serotonin/5-HT3 receptors1 • GI vagal afferent nerve fibers1 • Serotonin/5-HT3 receptors • Substance P/NK1 receptors 1. Hesketh PJ et al. Eur J Cancer. 2003;39(8):1074–1080. 2. Grunberg SM, Hesketh PJ. N Engl J Med. 1993;329(24):1790–1796. Illustration by Kirk Moldoff.

  8. Proposed pathways for CINV • CTZ activation • Blood • Cerebrospinal fluid Activated vomiting center Chemotherapy Increased afferent input to the CTZ and vomiting center Increased efferent output to target organs resulting in emesis • Cell damage • Release of neuroactive agents • Vagal activation Berger AM, Clark-Snow RA. In: DeVita VT Jr et al. 7th ed. Cancer: Principles & Practice of Oncology. Lippincott Williams & Wilkins; 2005:2515–2523. Illustration by Kirk Moldoff.

  9. Serotonin and 5­HT3 receptor pathway • Introduction of 5-HT3 receptor antagonists offered an improved treatment option.2 • Effective in acute vomiting; very limited efficacy for delayed events • Primary mechanism of action appears to be peripheral.2 1. Berger AM, Clark-Snow RA. In: DeVita VT Jr et al. 7th ed. Cancer: Principles & Practice of Oncology. Lippincott Williams & Wilkins; 2005:2515–2523. 2. Hesketh PJ et al. Eur J Cancer. 2003;39(8):1074–1080.

  10. Substance P and NK1 receptor pathway • Substance P relays noxious sensory information to the brain • High density of substance P/NK1 receptors located in brain. • NK1 receptor blockade effective for delayed vomiting: • Less effective for acute vomiting: needs a 5HT3 antagonist • Less effective for nausea: needs dexamethasone

  11. NK1 antagonists • Aprepitant 125mg 1 hour before chemotherapy on Day 1, 80mg Day 2 and Day 3 • SMC approved for cisplatin containing regimens (other regimens??) • Some interactions: clinical significance

  12. 5HT3 Antagonists • Block release of serotonin release from enterochromaffin cells in GI tract • Most effective for acute vomiting • All equally effective e.g ondansetron/granisetron (?palonesetron) • Best given as a stat dose pre-chemo • Oral and IV equally effective • Side effects: constipation, abdominal spasms, headaches

  13. Multi-Association of Supportive Cancer Care (MASCC) (See Handout)

  14. Dexamethasone • M.O.A not fully understood. • Very effective for nausea, acute and delayed vomiting • Acute: pre-dose before chemo • Delayed: 2-4 days after • Side effects: heartburn/indigestion, agitation, hiccups, abnormal BM’s (all manageable in most instances)

  15. DEXAMETHASONE

  16. Anticipatory N + V • Conditional response • Sights and smells • Involves higher cortical centres of brain • Occurs in 30% of patients • Lorazepam is an effective treatment

  17. Other situations… • Breakthrough symptoms - N + V in spite of optimal preventative treatment. • Rescue therapy - Treatment of breakthrough symptoms • Refractory - CINV recurs in subsequent cycles of therapy when all previous preventative and rescue treatments have failed.

  18. Breakthrough symptoms- which anti-emetic? • Less well-conducted trials available to guide treatment decisions. • Diagnosis of the cause of nausea and vomiting is crucial for deciding on which anti-emetic to use. • Key questions- when did symptoms start? when was last dose of chemo/XRT? When did steroid course stop? Nausea related to smells/taste of food? How many vomiting episodes? VAS to assess nausea? Appetite/food and fluid intake? • The only evidence available to rescue patients who have CINV is with the use of a D2 antagonist e.g. metoclopramide or a 5HT3 antagonist such as ondansetron. • Consider the side-effect profile of each anti-emetic. There may be more than one cause of nausea and vomiting therefore do not prescribe an anti-emetic that may worsen symptoms e.g. ondansetron and cyclizine may constipate- avoid if constipation and nausea present- use metoclopramide instead. • Severe cases- consider syringe driver for 48 hours then review. • Domperidone is supplied at a dose of 20mg qds with the majority of chemotherapy regimens. Consider if you want to add or substitute. If patient feels ineffective- consider compliance in view of low confidence in medicine.

  19. Effective control • Give appropriate antiemetic medicines before chemo and after at correct dose, route, frequency, duration and timing • Start “prophylaxis” Cycle 1 and then throughout • “Breakthrough symptoms”- diagnosis cause and chose anti-emetic wisely (consider anti-emetic choice, dose, frequency, duration and side effect profile). • Counsel patient on diet when feeling sick or vomiting- importance of small amounts of food frequently (5-6 meals instead of 3), plenty fluid, eat easy to swallow foods with minimal smell e.g. clear broth, white toast, yoghurt, custard, crackers.

  20. Any Questions?

More Related